Table 1.

Characteristics during baseline for Frequent Hemodialysis Network (FHN) patients

VariablesDaily TrialNocturnal Trial
Three Times/Wk (n=120; Conventional)Six Times/Wk (n=125; Daily) Three Times/Wk (n=42; Conventional)Six Times/Wk (n=45; Nocturnal)
Age (yr)52.0±14.148.9±13.654.0±12.951.7±14.4
Men73 (60.8%)78 (62.4%)28 (66.7%)29 (64.4%)
Race/ethnicity
 Black53 (44.2%)49 (39.2%)11 (26.2%)12 (26.7%)
 White46 (38.3%)43 (34.4%)21 (50.0%)27 (60.0%)
 Native American, Aboriginal Canadian, Alaskan Native, First Nation4 (3.3%)4 (3.2%)2 (4.8%)1 (2.2%)
 Asian5 (4.2%)11 (8.8%)7 (16.7%)5 (11.1%)
 Native Hawaiian or other Pacific Islander3 (2.5%)1 (0.8%)0 (0%)0 (0%)
 Other/mixed/unknown9 (7.5%)17 (13.6%)1 (2.4%)0 (0%)
Hispanic/Latino ethnicity31 (26%)38 (30%)0 (0%)0 (0%)
ESRD vintage (yr)a3.40 (0.58, 12.94)3.85 (0.69, 17.31)0.53 (0.10, 6.00)1.32 (0.09, 12.55)
Weekly standard Kt/V2.53±0.392.50±0.312.34±0.342.35±0.28
Residual urinary volume (L/d)a0 (0, 0.54)0 (0, 0.60)0.54 (0, 1.25)0.40 (0, 1.33)
Residual renal urea clearance (ml/min)
 072 (60.0%)90 (72.0%)11 (26.2%)13 (28.9%)
 >0–119 (15.8%)18 (14.4%)9 (21.4%)7 (15.6%)
 >1–327 (22.5%)15 (12.0%)14 (33.3%)14 (31.1%)
 >32 (1.7%)2 (1.6%)8 (19.0%)11 (24.4%)
Hypertension111 (92.5%)117 (93.6%)39 (92.9%)41 (91.1%)
Coronary artery disease16 (13.3%)11 (8.8%)4 (9.5%)5 (11.1%)
Congestive heart failure24 (20.0%)25 (20.0%)7 (16.7%)5 (11.1%)
Atrial fibrillation9 (7.5%)5 (4.0%)0 (0.0%)6 (13.3%)
Peripheral arterial disease10 (8.33%)15 (12.0%)7 (16.7%)8 (17.8%)
Stroke9 (7.5%)9 (7.2%)1 (2.4%)1 (2.2%)
Diabetes50 (41.7%)50 (40.0%)18 (42.9%)19 (42.2%)
COPD5 (4.2%)6 (4.8%)2 (4.8%)2 (4.4%)
Liver disease1 (0.8%)1 (0.8%)1 (2.4%)0 (0%)
Dialysis access
 Fistula72 (59.2%)83 (65.8%)18 (41.9%)24 (51.1%)
 Graft23 (18.9%)22 (17.5%)4 (9.3%)3 (6.4%)
 Catheter27 (22.1%)21 (16.7%)21 (48.8%)20 (42.6%)
Antihypertensives105 (87.5%)109 (87.2%)35 (83.3%)38 (84.4%)
ACEI38 (31.7%)42 (33.6%)12 (28.6%)7 (15.6%)
ARB25 (20.8%)30 (24.0%)3 (7.1%)9 (20.0%)
Dihydropyridine CCB53 (44.2%)62 (49.6%)15 (35.7%)18 (40.0%)
Nondihydropyridine CCB6 (5.0%)6 (4.8%)3 (7.1%)2 (4.4%)
β-Blockers77 (64.2%)70 (56.0%)21 (50.0%)30 (66.7%)
Peripheral α-blockers4 (3.3%)1 (0.8%)4 (9.2%)2 (4.4%)
Centrally acting agents24 (20.0%)22 (17.6%)3 (7.1%)5 (11.1%)
Nonspecific vasodilators13 (10.8%)22 (17.6%)0 (0%)2 (4.4%)
Diuretics16 (13.3%)17 (13.6%)6 (14.3%)11 (24.4%)
  • Results are shown as mean ± SD or frequency (%) as appropriate. Patients may have more than one hemodialysis access at baseline. COPD, chronic obstructive pulmonary disease; ACEI, angiotension converting enzyme inhibitor ARB, angiotensin receptor blocker; CCB, calcium channel blocker.

  • a For ESRD and residual urine volume, the 10th and 90th percentiles are given.